AllianceBernstein
LUCD icon

AllianceBernstein’s Lucid Diagnostics LUCD Stock Holding History

AllianceBernstein’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.3K Buy
47,200
+25,000
+113% +$26.9K ﹤0.01% 3289
2026
Q1 		$24.2K Hold
22,200
– – ﹤0.01% 3218
2025
Q4 		$24.2K Hold
22,200
– – ﹤0.01% 3227
2025
Q3 		$22.4K Hold
22,200
– – ﹤0.01% 3237
2025
Q2 		$25.5K Buy
+22,200
New +$28.7K ﹤0.01% 3227

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

AllianceBernstein's LUCD Position: Q2 2026 in Review

AllianceBernstein increased its Lucid Diagnostics (LUCD) stake by 113% in Q2 2026, buying an estimated $26.9K and bringing the position to 47,200 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3289.

AllianceBernstein first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • AllianceBernstein held 47,200 shares of Lucid Diagnostics worth $54.3K as of Q2 2026.
  • AllianceBernstein bought 25,000 Lucid Diagnostics shares in Q2 2026, an estimated $26.9K.
  • Lucid Diagnostics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3289 holding.
  • AllianceBernstein first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.